Veeva Systems Inc. $VEEV Shares Bought by Cumberland Partners Ltd

Cumberland Partners Ltd increased its holdings in Veeva Systems Inc. (NYSE:VEEV) by 8.7% during the second quarter, HoldingsChannel.com reports. The fund owned 12,500 shares of the technology company’s stock after buying an additional 1,000 shares during the period. Cumberland Partners Ltd’s holdings in Veeva Systems were worth $3,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC acquired a new position in shares of Veeva Systems during the first quarter worth about $365,684,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Veeva Systems by 20.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after buying an additional 689,700 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Veeva Systems by 423.8% in the second quarter. Los Angeles Capital Management LLC now owns 841,303 shares of the technology company’s stock valued at $242,278,000 after buying an additional 680,702 shares in the last quarter. Linonia Partnership LP grew its holdings in Veeva Systems by 52.7% during the first quarter. Linonia Partnership LP now owns 1,836,557 shares of the technology company’s stock worth $425,402,000 after acquiring an additional 633,585 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Veeva Systems by 48.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,799,931 shares of the technology company’s stock worth $416,918,000 after acquiring an additional 585,785 shares in the last quarter. 88.20% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Veeva Systems news, insider Thomas D. Schwenger sold 3,350 shares of Veeva Systems stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $300.04, for a total value of $1,005,134.00. Following the completion of the sale, the insider owned 23,773 shares in the company, valued at $7,132,850.92. The trade was a 12.35% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jonathan Faddis sold 720 shares of the stock in a transaction dated Monday, October 6th. The stock was sold at an average price of $298.12, for a total transaction of $214,646.40. Following the transaction, the senior vice president owned 7,868 shares in the company, valued at approximately $2,345,608.16. The trade was a 8.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 24,665 shares of company stock valued at $7,438,000. Insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on VEEV shares. BMO Capital Markets initiated coverage on shares of Veeva Systems in a research report on Thursday, November 13th. They set a “market perform” rating and a $300.00 target price on the stock. Stifel Nicolaus lifted their price target on shares of Veeva Systems from $295.00 to $320.00 and gave the company a “buy” rating in a research report on Thursday, August 28th. Oppenheimer restated an “outperform” rating and issued a $325.00 price target on shares of Veeva Systems in a report on Thursday, August 28th. Needham & Company LLC reiterated a “buy” rating and set a $355.00 target price on shares of Veeva Systems in a research report on Friday, October 17th. Finally, UBS Group raised their price target on Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research report on Thursday, August 28th. Seventeen equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $307.28.

Veeva Systems Trading Down 0.2%

Shares of VEEV stock opened at $273.21 on Thursday. The company has a market capitalization of $44.78 billion, a price-to-earnings ratio of 56.10, a PEG ratio of 2.22 and a beta of 0.98. The firm has a 50-day moving average price of $288.57 and a 200 day moving average price of $278.53. Veeva Systems Inc. has a twelve month low of $201.54 and a twelve month high of $310.50.

Veeva Systems (NYSE:VEEV) last announced its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.90 by ($0.64). Veeva Systems had a net margin of 27.29% and a return on equity of 13.72%. The firm had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. During the same period in the previous year, the company posted $1.62 EPS. The business’s quarterly revenue was up 16.7% on a year-over-year basis. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. As a group, research analysts predict that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.